این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Pediatric Hematology and Oncology، جلد ۴، شماره ۱، صفحات ۳۲-۳۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Assessment of Thiopurine–based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia
چکیده انگلیسی مقاله For the past half century, thiopurines have earned themselves a reputation as effective anti-cancer and immunosuppressive drugs. Thiopurine S-methyltransferase (TPMT) is involved in the metabolism of all thiopurines and is one of the main enzymes that inactivates mercaptopurine. 6-MP is now used as a combination therapies for maintenance therapy of children with acute lymphocytic leukemia (ALL). In all patients receiving mercaptopurine, there is a risk of bone marrow suppression. TPMT activity is inherited as a monogenic, co-dominant trait. More than 25 variants are known. Genetic testing is available for several TPMT variant alleles. Most commonly TPMT*2, *3A, and *3C are tested for, which account for >90% of inactivating alleles. Differences in DNA that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals.Genotyping may become part of routine investigations to help clinicians tailor drug treatment effectively. This success is mainly due to the development of combination therapies and stratification of patients according to risk of treatment failure and relapse, rather than the discovery of new drugs. The aim of this study was to investigate the effect of genotype or methyltransferase enzyme activity before starting therapy in children with ALL. This can prevent the side effect of thiopurine drugs. In fact, the common polymorphism of this enzyme in population could be a prognostic factor in relation to drug use and treatment of patients with ALL.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله f عظیمی | f azimi
m.s.c student of medical genetics, zanjan university of medical science, zanjan, iran

سازمان اصلی تایید شده: دانشگاه زنجان (Zanjan university)

m جعفریان | m jafariyan
m.s.c student of medical genetics, zanjan university of medical science, zanjan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی زنجان (Zanjan university of medical sciences)

s خاتمی | s khatami
phd student of molecular medicine, zanjan university of medical science, zanjan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی زنجان (Zanjan university of medical sciences)

y مرتضوی | y mortazavi
associate professor of hematology zanjan university of medical sciences, zanjan,iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی زنجان (Zanjan university of medical sciences)

m آزاد | m azad
assistant professor in hematology, ghazvin university of medical science, ghazvin,iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی زنجان (Zanjan university of medical sciences)

نشانی اینترنتی http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-70-7&slc_lang=en&sid=en
فایل مقاله دریافت فایل مقاله
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات